Levemir FlexPen

Levemir FlexPen 100iu/ml 3ml 1`s

KSh2,000.00

Share On

Product Description

Levemir FlexPen is indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus.

  • Levemir® is not recommended for the treatment of diabetic ketoacidosis.
  • Levemir® is contraindicated during episodes of hypoglycemia and in patients hypersensitive to Levemir® or any of its excipients. Reactions have included anaphylaxis.
  • Never Share a Levemir® FlexTouch® Pen, Needle, or Syringe Between Patients
  • Hyperglycemia or Hypoglycemia with Changes in Insulin Regimen: Changes in an insulin regimen may affect glycemic control and predispose to hypoglycemia or hyperglycemia.
  • Hypoglycemia: Hypoglycemia is the most common adverse reaction of insulin, including Levemir®, and may be life-threatening.
  • Hypersensitivity and Allergic Reactions: If hypersensitivity reactions occur, discontinue Levemir®; treat per standard of care and monitor until symptoms and signs resolve. Levemir® is contraindicated in patients who have had hypersensitivity reactions to insulin detemir or any of the excipients.
  • Hypokalemia: All insulin products, including Levemir®, cause a shift in potassium from the extracellular to intracellular space, possibly leading to hypokalemia.
  • Fluid Retention and Heart Failure with Concomitant Use of PPAR-gamma Agonists: Thiazolidinediones (TZDs), which are peroxisome proliferator-activated receptor (PPAR)-gamma agonists, can cause dose-related fluid retention, particularly when used in combination with insulin